News

As per the agreement, Actelion will receive exclusive rights to commercialize XIAFLEX (collagenase clostridium histolyticum) in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals.

CliniWorks’ AccelFind software will be interfaced to Southampton’s clinical systems to extract and de-identify information about cancers and other diseases, and heart and blood conditions from one million

The primary objective of the placebo-controlled study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic profile of single ascending doses of Vasomera administered subcutaneously to patients with essential

Silenor could be the first and only prescription therapy for insomnia in Canada that is not a controlled substance, if approved. Paladin has gained commercialization rights to Silenor

The company has submitted new drug application (NDA) for Qnexa in October 2011. Qnexa is an investigational drug candidate being developed to address weight loss, type 2 Diabetes

The status will allow Eurogentec to manufacture a commercial bulk parenteral biopharmaceutical for one of its clients for the US market. Eurogentec CEO Jean-Pierre Delwart said they anticipate

LIGHT is a small molecule imaging agent that is believed to have potential for selective detection of tumors and metastases in a range of cancers. LIGHT is comprised

Trappsol Cyclo product is an orphan drug-designated treatment for Niemann Pick Type-C disease, also known as Childhood Alzheimer’s. The product is currently being administered in the US under

The Smarticles delivery technology has been licensed to ProNAi, for delivery of single-stranded oligonucleotide therapeutics and to Mirna for delivery of double-stranded microRNA mimics. Marina R&D executive vice